Find information on thousands of medical conditions and prescription drugs.

Cisapride

Cisapride is a parasympathomimetic which acts as a serotonin 5-HT4 agonist. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system. It is sold under the trade names Prepulsid (Janssen-Ortho) and Propulsid (in the U.S.). more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Clinical uses

Cisapride increases muscle tone in the esophageal sphincter in people with gastroesophageal reflux disease. It also increases gastric emptying in people with diabetic gastroparesis. It has been used to treat bowel constipation.

In many countries it has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.

Sources

  • Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
  • Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4

Read more at Wikipedia.org


[List your site here Free!]


Increased Risk of Mortality with the Use of Cisapride
From American Family Physician, 5/1/00 by Monica Preboth

Cisapride (Propulsid), a prescription drug used in the treatment of severe nighttime heartburn in patients with gastroesophageal reflux disease, will be voluntarily removed from the U.S. market as of July 14, 2000. The effective date should allow enough time for patients and physicians to make alternative treatment decisions. After July 14, the manufacturer will continue to make the drug available to patients who meet specific clinical eligibility criteria for a limited-access protocol.

As of December 31, 1999, the use of cisapride has been associated with 341 reports of heart rhythm abnormalities, including 80 reports of mortality. Most of these adverse events occurred in patients who were taking other medications or had underlying conditions known to increase the risk of cardiac arrhythmia associated with cisapride.

Since cisapride was approved in 1993, the labeling has been revised several times to inform patients and physicians about the possible adverse effects. Despite these risk management efforts, the manufacturer has decided that access to the drug poses unacceptable risks and will remove it from the U.S. market.

Patients who are using cisapride should contact their physicians to discuss alternative treatment options. Physicians who are treating patients with severely debilitating conditions for whom they believe the benefits of cisapride may still outweigh the risks are encouraged to contact Janssen at 800-JANSSEN (800-526-7736). More information on the voluntary removal of cisapride from the U.S. market can be obtained by calling the FDA at 888-INFO-FDA (888-463-6332). This information can also be accessed on the FDA Web site (http:// www.fda.gov).

COPYRIGHT 2000 American Academy of Family Physicians
COPYRIGHT 2000 Gale Group

Return to Cisapride
Home Contact Resources Exchange Links ebay